United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024. At ATS, United Therapeutics will host an educational industry theater on implementing treprostinil induction strategies in pulmonary hypertension, and the company is sponsoring the ATS 2024 Women’s Forum.

“We look forward to presenting the latest data on several of our key products and development programs,” said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics. “Notably, our academic and industry collaborators will present initial interim efficacy data from the ADVANCE EXTENSION open label extension evaluating extended-release ralinepag for pulmonary arterial hypertension and baseline data updates for the ongoing TETON studies in idiopathic pulmonary fibrosis. We are also pleased to unveil the exciting preliminary findings from our collaboration with Tempus, a leader in artificial intelligence and precision medicine, laying the foundation for earlier identification of patients with pulmonary hypertension.”

Posters, mini-symposia, and discussion sessions include:

Mini Symposium, Sunday, May 19, 10:03 to 10:15 a.m. PT: A14 – Metabolomic Signatures of Pulmonary Hypertension Associated with Interstitial Lung Disease: A Post-hoc Analysis of the INCREASE Study. Presented by Aaron B. Waxman, M.D., Ph.D., Brigham and Women’s Hospital.

Thematic poster session, Sunday, May 19, 11:30 a.m. to 1:15 p.m. PT: A46/P829 – Pulmonary Hypertension Screening Strategies in Patients with Interstitial Lung Disease: A Survey of PHINDER Study Sites. Presented by Eric Shen, PharmD, United Therapeutics.

Thematic poster session, Monday, May 20, 11:30 a.m. to 1:15 p.m. PT: B48/P1259 – TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis: Annual Update of Preliminary Baseline Data. Presented by Steven D. Nathan, M.D., Inova Fairfax Hospital.

Thematic poster session, Monday, May 20, 11:30 a.m. to 1:15 p.m. PT: B48/P1260 – Study Design and Rationale for the TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis. Presented by Steven D. Nathan, M.D., Inova Fairfax Hospital.

Thematic poster session, Tuesday, May 21, 11:30 a.m. to 1:15 p.m. PT: C62/P284 – Real-World Transition and Persistence to Oral Treprostinil Therapy from Parenteral Prostacyclins in Patients with Pulmonary Arterial Hypertension. Presented by Ali Ataya, M.D., University of Florida.